Accrued Expenses

3 Months Ended

12 Months Ended

Mar. 31, 2024

Dec. 31, 2023

Accrued Expenses

Accrued Expenses

Note 3. Accrued Expenses

The following is a summary of the Company’s accrued expenses:

	March 31,		December 31,
	2024		2023
Clinical trial expenses	$	2,070,955	$	1,993,784
Other		531,710		424,218
Total	$	2,602,665	$	2,418,002

Note 4.Accrued Expenses

The following is a summary of the Company’s accrued expenses:

	December 31,
	2023		2022
Clinical trial expenses	$	1,993,784	$	1,884,117
Other		424,218		423,629
Total	$	2,418,002	$	2,307,746